Literature DB >> 19135947

Early central nervous complications after umbilical cord blood transplantation for adults.

Hiroto Narimatsu1, Koichi Miyamura, Hiroatsu Iida, Motohiro Hamaguchi, Toshiki Uchida, Yoshihisa Morishita.   

Abstract

Early central nervous complications (CNS) are significant after allogeneic stem cell transplantation; however, the clinical characteristics of early CNS complications have not yet been well described. The medical record of 77 patients who underwent cord blood transplantation (CBT) between March 2001 and November 2005, at 8 centers of the Nagoya Blood and Marrow Transplantation Group were retrospectively reviewed. The preparative regimen included myeloablative CBT (n = 31) or reduced-intensity (RI)-CBT (n = 46). Of the 77 patients, 10 (13%) developed early CNS complications. Causes included Cyclosporine encephalopathy (n = 5), tacrolimus encephalopathy (n = 2), thrombocytic microangiopathy (n = 1), and unknown (n = 3). The median time of onset was 19 days (range: 2-58 days). All of the 10 patients developed impaired consciousness. Seizures developed in 6 patients. Early CNS complications spontaneously subsided in 3 patients. Three patients responded to cyclosporine or tacrolimus discontinuation. The remaining 4 patients died within 30 days of developing of early CNS complications. No relationship was detected between the preparative regimen and the onset of early CNS complications, while an HLA disparity showed borderline significance (hazard ratio, 3.24; 95% confidential interval, 0.94-11.20; P = .06). Early CNS complications are a significant problem after CBT, and the clinician has to be aware of the possibility of these complications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19135947     DOI: 10.1016/j.bbmt.2008.11.005

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  7 in total

1.  Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact.

Authors:  M R Dowling; S Li; B R Dey; S L McAfee; H R Hock; T R Spitzer; Y-B Chen; K K Ballen
Journal:  Bone Marrow Transplant       Date:  2017-11-13       Impact factor: 5.483

2.  Cerebrovascular disease after allogeneic hematopoietic stem cell transplantation: incidence, risk, and clinical outcome.

Authors:  Ting-An Lin; Jyh-Pyng Gau; Yao-Chung Liu; Po-Shen Ko; Hao-Yuan Wang; Sheng-Hsuan Chien; Chia-Jen Liu; Liang-Tsai Hsiao; Tzeon-Jye Chiou; Jin-Hwang Liu
Journal:  Int J Hematol       Date:  2019-03-12       Impact factor: 2.490

3.  Neurological complications of transplantation: part I: hematopoietic cell transplantation.

Authors:  Amy A Pruitt; Francesc Graus; Myrna R Rosenfeld
Journal:  Neurohospitalist       Date:  2013-01

4.  Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes.

Authors:  Lawrence Chang; David Frame; Thomas Braun; Erin Gatza; David A Hanauer; Shuang Zhao; John M Magenau; Kathryn Schultz; Hemasri Tokala; James L M Ferrara; John E Levine; Pavan Reddy; Sophie Paczesny; Sung Won Choi
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-02       Impact factor: 5.742

5.  Early central nervous system complications after allogeneic hematopoietic stem cell transplantation in children.

Authors:  Kyung Nam Koh; Meerim Park; Bo Eun Kim; Ho Joon Im; Jong Jin Seo
Journal:  Korean J Hematol       Date:  2010-09-30

6.  High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.

Authors:  J R Long-Boyle; K G Green; C G Brunstein; Q Cao; J Rogosheske; D J Weisdorf; J S Miller; J E Wagner; P B McGlave; P A Jacobson
Journal:  Bone Marrow Transplant       Date:  2010-04-12       Impact factor: 5.483

Review 7.  New perspectives in human stem cell therapeutic research.

Authors:  Alan Trounson
Journal:  BMC Med       Date:  2009-06-11       Impact factor: 8.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.